Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wisinski

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
The Oncologist|April 20, 2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate CancerNeeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, et al.
Clinical Breast Cancer|December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network studyMark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
Oncoimmunology|February 7, 2019
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic modelJose M Ayuso, Regan Truttschel, Max M Gong, et al.
The American Journal of Pathology|February 13, 2018
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma PatientsKarla Esbona, Yanyao Yi, Sandeep Saha, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 13, 2024
The prostaglandin E<sub>2</sub> EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesityJoshua C Neuman, Austin Reuter, Kathryn A Carbajal, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Molecular Cancer Therapeutics|November 21, 2015
Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast CancerAlka Choudhary, Brittany Zachek, Robert F Lera, et al.
Cancer|November 24, 2020
Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network studyAmye J Tevaarwerk, Kris Kwekkeboom, Kevin A Buhr, et al.
Cancer|June 18, 2021
Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitationsAmye J Tevaarwerk, Kris Kwekkeboom, Kevin A Buhr, et al.
Oncogene|March 1, 2026
Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasisAbbey E Williams, Erica J Hoffmann, David R Inman, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
The Oncologist|April 20, 2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate CancerNeeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, et al.
Clinical Breast Cancer|December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network studyMark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
Oncoimmunology|February 7, 2019
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic modelJose M Ayuso, Regan Truttschel, Max M Gong, et al.
The American Journal of Pathology|February 13, 2018
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma PatientsKarla Esbona, Yanyao Yi, Sandeep Saha, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 13, 2024
The prostaglandin E<sub>2</sub> EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesityJoshua C Neuman, Austin Reuter, Kathryn A Carbajal, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Molecular Cancer Therapeutics|November 21, 2015
Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast CancerAlka Choudhary, Brittany Zachek, Robert F Lera, et al.
Cancer|November 24, 2020
Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network studyAmye J Tevaarwerk, Kris Kwekkeboom, Kevin A Buhr, et al.
Cancer|June 18, 2021
Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitationsAmye J Tevaarwerk, Kris Kwekkeboom, Kevin A Buhr, et al.
Oncogene|March 1, 2026
Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasisAbbey E Williams, Erica J Hoffmann, David R Inman, et al.
Pageof 14